What the business is, and whether it's a good one at a fair price.
Manufactures pharmaceutical products and recently commenced operations in Kenya. Facilities received a WHO inspection closure report, indicating compliance with WHO manufacturing standards, and reportedly use 55 to 60 percent renewable energy. For FY26, the company reported revenue of Rs 927.11 crore with an EBITDA margin of 25.36 percent. The cost structure is materials-heavy at 41.7 percent of revenue, followed by other operating expenses at 21.7 percent and employee costs at 14.7 percent. A leadership transition took effect in July 2026, with Mr. Rahul Adakmol, previously at Dr. Reddy's, Bharat Serums and Reliance, appointed CEO from July 15, 2026.
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
How has the market priced it — with filings on the timeline?
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
How does it stack up on valuation, returns and growth?
Loading peers…
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Answered from BLISS GVS PHARMA LTD's filed financials and exchange disclosures
BLISS GVS PHARMA LTD is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol BLISSGVS.
Yes. Over the trailing twelve months BLISS GVS PHARMA LTD reported a net profit of ₹142 Cr on revenue of ₹1,005 Cr.
Yes. The dividend yield is 0.14% at the current price. It paid out 8% of its profit as dividend in FY26.
Effectively yes. It holds ₹32 Cr more cash than debt. Debt stands at 0.00× equity.
On trailing P/E, BLISS GVS PHARMA LTD ranks 132 of 169 in Pharmaceuticals — cheaper than 22% of them, against an industry median of 28.9×. This is a position, not a valuation judgement.
On a typical session BLISS GVS PHARMA LTD moves 1.76% — that is the median absolute close-to-close move across its last 269 trading days. Announcement days are routinely larger.
Every NSE and BSE filing by BLISS GVS PHARMA LTD appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.
